Proteros and Eisai Co., Ltd Enter into Integrated Lead Discovery Collaboration
News Apr 16, 2012
Proteros biostructures GmbH announce that the company has entered into a research collaboration with Eisai Co., Ltd (Japan) to identify small molecule inhibitors against a target selected by Eisai in the field of immunology.
Under the agreement Proteros will deliver a novel lead compound applying its integrated lead discovery platform that includes X-Ray structural biology, biophysical screening and profiling, novel fragment libraries and medicinal chemistry expertise.
Dr. Klaus Hinterding, Proteros CSO, stated: "We are very pleased to further deepen our existing relationship with Eisai by being selected as partner for this important program. We look forward to contributing to the success of Eisai's research activities using our unique technology platform."
A New Tactic in the Fight Against Drug-Resistant InfectionsNews
$1 million research grant could lead to life-saving antibiotics.READ MORE